Clinical Trial Update: Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis [Phase 2]

View source ↗

Summary

Phase 2 trial update on repeat-dose evinacumab for severe hypertriglyceridemia at risk for acute pancreatitis, with completed status and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• Evinacumab (evinacumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Severe Hypertriglyceridemia (sHTG) | Phase 2 | Status: COMPLETED | Results posted: 2023-02-16